O lder adults, particularly those admitted to the hospital, are vulnerable to adverse drug events in the context of polypharmacy. Common potentially harmful medications include benzodiazepine and nonbenzodiazepine sedative hypnotics, such as the "Z-drugs" (zopiclone, zolpidem, zaleplon); these are often prescribed for sleep in older adults despite organizations such as the American Society of Geriatrics and Choosing Wisely recommending against their use as a first choice for insomnia, agitation, and delirium. 1 As many as one-third of older adults receive sedative drugs while hospitalized, including new prescriptions that are perpetuated at discharge, placing people at risk of cognitive deterioration, falls, fractures, and death. 2, 3 In 2014, the Eliminating Medications through Patient Ownership of End Results (EMPOWER) trial demonstrated that a self-directed educational pamphlet, complete with tapering instructions, was a safe and effective intervention for chronic benzodiazepine use in older adults residing in the community. By mailing the brochure in a pharmacy-based cluster randomized trial, the study achieved a sustained 6-month reduction in benzodiazepines use, with 27% of community-dwelling adults discontinuing, compared with 5% of those receiving usual care. 4 In 2017, using knowledge questionnaires, a post hoc analysis of the trial demonstrated that individuals with mild cognitive impairment were able to acquire new knowledge about the harms of sedatives from the informational pamphlet. The intervention was just as successful when comparing individuals with impaired and normal cognition who received the intervention. 5 Although physicians often perpetuate prescriptions for potentially inappropriate medications, patients also have a role to play in deprescribing. Informing older adults about the harms of certain medications is an approach that can prompt an initial conversation between an individuals and his or her physician or pharmacist about deprescribing. 6 We hypothesized that the consumer-directed EMPOWER pamphlet (http://www.criugm.qc.ca/fichier/pdf/BENZOeng.pdf), coupled with significant contact with the healthcare system at the time of hospitalization, could provide an opportunity for deprescribing sedatives in a population of at-risk older adults.
METHODS
This single-arm intervention study using a comparison cohort took place on our 52-bed medical teaching unit (Royal Victoria Hospital, Montr eal, Canada). All inpatients aged 65 and older with a sedative prescription were screened. Inclusion criteria were self-or caregiver-reported minimum weekly use in the previous month and at least 3 doses in the week before admission. Dispensing was confirmed using the provincial electronic pharmacy record, the Dossier Sant e Qu ebec. Individuals admitted for alcohol withdrawal, with a seizure disorder, or clearly identified with a life expectancy of less than 3 months (according to the treating team) were excluded.
At recruitment, frailty was assessed using a validated 7-point scale, 7 and individuals were interviewed regarding prehospitalization sleep quality, 8 falls, and sedative use. Recruitment could occur at any time during hospitalization, but the majority of participants were recruited during the first 48 hours of their stay. The only intervention was receipt of the EMPOWER brochure and encouragement to speak with the treating team if a participant was interested in sedative cessation. The medical team did not receive any specific academic detailing. Thirty days after discharge, participants were re-interviewed over the telephone about their sedative use, which was confirmed through outpatient pharmacy records, and about the quality of their sleep since leaving the hospital. The study continued until 50 participants were interviewed 30 days after discharge.
The proportion of sedatives deprescribed in the hospital in intervention participants was compared using the chi-square test with that of a cohort of inpatients from the same unit 9 who had not received this or any other intervention. The proportion of sedatives deprescribed in the comparison cohort was determined during the year before the intervention (between December 2013 and April 2015). Deprescribing in this cohort was determined from the best possible medication history at admission and the discharge prescription. A trained clinical pharmacist takes a medication history for all individuals admitted to the medical unit. Ongoing sedative use was documented in all individuals on the day of discharge.
Because resident and faculty physicians move between units, a contemporaneous control cohort was not feasible. We also compared the proportion of sedatives deprescribed in the hospital with the proportion of sedatives deprescribed in the community in a prior study using the EMPOWER brochure (comparison made using the chisquare test). Sleep disturbance scores (Patient-Reported Outcomes Measurement Information System Sleep Disturbance Form 4a) from before and after hospitalization were compared using the Wilcoxon matched-pairs signedrank test.
The McGill University Health Centre Research Ethics Board approved this study, which was performed without external funding.
RESULTS
Sixty-five individuals were approached, and 62 agreed to participate. (Table 1 lists characteristics of the intervention cohort.) The characteristics of the control group have been described previously and did not differ significantly from those of the intervention group. 9 The median age was 79 (interquartile range 71-84), 69% were moderately to severely frail, and 42% reported a fall within the preceding month. Twelve did not achieve 30-day follow up because they died in hospital or within 30 days. None of the deaths were related to the study intervention. Sedatives were successfully deprescribed at 30 days after discharge in 32 (64%) of those who achieved 30 days of follow-up, which was significantly higher than our historical baseline rate of 21% (42/202, p<.001).
In the intervention group, significantly more sedative discontinuation was seen at 30 days after discharge in those who initiated the tapering process while they were still in the hospital than in those who waited until after hospital discharge to initiate. The treating team introduced a deprescribing plan for 36 participants while they were still in the hospital, of whom 29 (81%) had sustained stops 30 days after discharge. By contrast, only 3 of the remaining 14 (21%) participants who commenced the deprescribing process after hospital discharge had successfully stopped 30 days after discharge (p<.001) ( Table 2) .
Of the 47 (94%) participants who consented to a 30-day follow-up telephone interview, self-reported sleep disturbance was no worse than prehospitalization selfreported sleep (Table 3 ; median T-scores 56.1 vs 54.3; p5.35). There were no episodes of acute withdrawal.
DISCUSSION
We provided hospitalized older adults, many of whom were moderately to severely frail, with educational material detailing the harms of chronic sedative use along with instructions on how to taper and stop them and achieved a short-term but sustained 64% discontinuation 30 days after discharge. We did not observe deterioration in sleep quality or precipitation of withdrawal. To our knowledge, this is the first intervention targeting chronic sedative use in hospitalized individuals; other studies have demonstrated success with interventions aimed at community-dwelling adults. 4, [10] [11] [12] Prior interventions have included education, tapering, and pharmacological substitution with melatonin. In these studies, as well as ours, withdrawal symptoms were uncommon, and sleep quality did not deteriorate. A recent meta-analysis showed that discontinuation rates can vary from 27% to 80%, depending on the methodology used. 13 Our rates of discontinuation were significantly higher than the 27% (40/148; p<.001) seen in the original EMPOWER trial, in which participants were mailed a copy of the brochure at home. Although there is an important role for deprescribing initiatives targeted at outpatients, hospitalization may provide a special context to engage people in the process of deprescribing, coupled with the opportunity to immediately initiate a conversation with a knowledgeable healthcare provider. Context, opportunity, and motivation can be critical factors leading to a successful outcome of stopping medications. 14 Limitations of our study include lack of power to assess for an effect on reduction in sedative-related adverse drug events. Furthermore, multivariate analysis was not possible, limiting the ability to draw a causal link between the administration of the EMPOWER brochure and successful deprescribing on the medical ward. In addition, this study took place in a single center that has a preexisting culture of deprescribing. 15 Nonetheless, in the absence of any other concurrent intervention, our rates were markedly higher than what we have achieved historically when compared over a long period during which we admitted a similarly complex control group. Individuals in the control and intervention groups had similar burdens of chronic disease, mortality, and length of stay. In addition, frequency of sedative use (not duration) in intervention participants was, if anything, heavier than in the control group. Anyone who was using a sedative medication fewer than three times per week was excluded from the intervention, whereas all controls prescribed sedative-hypnotics were included, even occasional users.
Although generalizability is a concern, the intervention previously proved effective in an unselected ambulatory population, in the original EMPOWER trial, including individuals with mild cognitive impairment, and does not require significant resources to implement, making it ideal for broad dissemination. We speculate that our improved success rate reflects the captive audience of hospitalized individuals, with admission to the hospital representing an ideal pairing of motivation and opportunity for deprescribing sedatives because of daily physician contact. Furthermore, individuals hospitalized with a recent fall (half of our study population) may be primed for such an intervention and highly motivated to stop a culprit medication to regain or maintain autonomy.
CONCLUSION
This pilot study demonstrates that it is feasible and safe to administer EMPOWER to hospitalized individuals. In individuals who received the brochure, there was an increase: deprescribing increased (ie more sedatives were stopped) at 30 days after discharge and no worsening of self-reported sleep. Our study suggests an important role for inpatient educational deprescribing initiatives targeting high-risk or low-value medications. Direct-to-patient detailing addresses many barriers to deprescribing such as time and resource constraints, as well as gaps in consumer and provider knowledge. Future studies are required to determine whether this type of consumer education leads to sustained and effective results, such as a reduction in adverse drug events for frail, medically complex adults with polypharmacy.
